+39 06 5782665
contact@donawa.com
Italy - UK - USA

COMPANY NEWS

Maria Donawa to speak at the 9th EAAR Annual Conference on 24-25 February 2025

The 9th EAAR Annual Conference on New Medical Device Regulations (RMD 2025) will take place in Brussels, Belgium, on 24-25 February 2025, featuring speakers from across the MedTech industry, including regulators and notified bodies. Organized by the European Association of Authorised Representatives (EAAR), the conference serves as an inclusive platform for all stakeholders across the…

December 4, 2024
No Comments
Clinical Data Requirements: EU vs. US – Critical Differences and Strategies

On 25 September 2024, Donawa Lifescience President Dr. Maria E. Donawa spoke at the webinar titled ‘Clinical Data Requirements: EU vs. US – Critical Differences and Strategies’. Dr. Donawa was joined as a speaker by Tom Melvin, Associate Professor of Medical Device Regulatory Affairs, Trinity College, Dublin. The webinar was hosted by MedTech Leading Voice…

October 21, 2024
No Comments
Maria Donawa posts a second article on device clinical evaluation plans on LinkedIn

Donawa Lifescience President, Maria E. Donawa, M.D., has authored a second ‘Regulatory Recap’ article on LinkedIn covering interpretational difficulties with requirements for Clinical Evaluation Plans (CEPs) under the EU Medical Device Regulation (MDR, 2017/745) titled: ‘CEPs: What Does “State of the Art” Modify?’ The topic arises because of confusion among manufacturers, notified bodies, and competent…

September 9, 2024
No Comments
Maria Donawa interviewed by MEDTECH INSIGHT

Donawa Lifescience President, Maria E. Donawa, M.D., has been interviewed by Amanda Maxwell of MEDTECH INSIGHT on the subject of European medical device guidance document MDCG 2024-3 concerning clinical investigation plans in the journal dated 8 April 2024. The guidance, full title ‘Guidance on the content of the clinical investigation plan for clinical investigations of…

April 12, 2024
No Comments
Maria Donawa posts article on device clinical evaluation plans on LinkedIn

Donawa Lifescience President, Maria E. Donawa, M.D., has authored a ‘Regulatory Recap’ article on LinkedIn titled ‘CEPs: Parameters vs outcome parameters, what’s the difference?’ The topic arises because of confusion among manufacturers, notified bodies, and competent authorities regarding the interpretation of certain requirements of the EU Medical Device Regulation (MDR, 2017/745) for clinical evaluation plans…

April 3, 2024
No Comments
Maria Donawa spoke at the 8th EAAR Annual Conference on 26-27 February 2024

The 8th EAAR Annual Conference on New Medical Device Regulations (RMD2024) took place in Brussels, Belgium, on 26-27 February 2024, featuring speakers from across the MedTech industry, including regulators and notified bodies. Organized by the European Association of Authorised Representatives (EAAR), the conference served as an inclusive platform for all stakeholders across the both medical…

March 20, 2024
No Comments
Donawa Lifescience personnel spoke at CTRMD2023 Conference

Donawa Lifescience VP Operations and Clinical Affairs, Daniela Karrer, and Director, Clinical Affairs, both delivered papers at The American Conference on Clinical Trials and Regulation of Medical Devices, which took place in Orlando, Florida, USA, from 20 to 21 November 2023. The conference was intended to be of special interest to regulatory affairs, clinical trials,…

December 13, 2023
No Comments
Maria Donawa presented on EU/US differences at Vienna Conference on Clinical Studies

Donawa Lifescience President, Maria E. Donawa M.D., spoke at the ​2nd Conference on Clinical Studies with Medical Devices and IVDs, which took place in Vienna, Austria, on 30-31 March 2023. This year’s conference was designed to provide a wealth of information for both medical device and in vitro diagnostic clinical investigations, with a particular focus…

June 18, 2023
No Comments
Donawa Lifescience opens GB company to provide UKRP services

Donawa Lifescience Consulting (DLC), headquartered in Rome, Italy, has announced the opening of a company in Great Britain (GB), Donawa Lifescience Ltd., to provide non-UK companies with ‘United Kingdom Responsible Person’ (UKRP) services as an easy initial pathway to the post-Brexit medical device market in Great Britain. Following the publication of the UK Medicines and…

October 23, 2020
No Comments
Maria Donawa authors new White Paper for BSI Compliance Navigator

Donawa Lifescience President, Maria E. Donawa M.D., has authored a new White Paper for inclusion in BSI’s Compliance Navigator series, titled ‘Medical device clinical investigations – What’s new under the MDR?’ The 30 page document discusses the important new requirements for pre-market and post-market clinical investigations included in the European Medical Device Regulation (MDR, 2017/745),…

September 15, 2020
No Comments
  • 1
  • 2